Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primary efficacy endpoint of change at Day 28 from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a patient-reported outcome (PRO) tool used to measure health-related quality of life for people with CF. Data from the 164-patient, double-blinded, randomized study demonstrated a significant improvement in the CFQ-R, with a treatment difference in mean change from baseline of 9.7 points in the respiratory domain (on a scale of 100) compared to placebo (p less than 0.001) following a 28-day treatment course with 75 mg aztreonam lysine for inhalation or volume-matched placebo administered three times daily by the PARI eFlow(R) Electronic Nebulizer. Aztreonam lysine-treated patients also experienced significant improvements at Day 28 in respiratory function, as measured by relative improvement of FEV1, with a treatment difference in mean change from baseline of 10.3 percent versus placebo (p less than 0.001). Full study results will be submitted for presentation at an upcoming scientific meeting.

The most common treatment-emergent adverse events in this study were cough, productive cough, nasal congestion, sore throat and dyspnea (shortness of breath). The incidences of these events were not significantly different between the placebo and the aztreonam lysine groups.

"The FDA, Cystic Fibrosis Foundation and medical community have identified PROs as important endpoints in clinical trials for CF and a variety of other diseases," said A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics, Gilead Sciences. "AIR-CF1 is the first Phase II
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. 20, ... , the Canadian Medical Association (CMA) voted on and ... plant material, including medicinal cannabis. Bedrocan Cannabis Corp., a ... of the CMA motion. The CMA is ... hazards associated with smoking any plant material, including medicinal ...
(Date:8/22/2014)... COLUMBUS, Ohio , Aug. 22, 2014 MC ... Devices Inc. (MID), a Columbus, OH ... to distribute the FloShield laparoscopic and robotic visualization system in ... will be approved for sale in Japan ... has a long-time experience and an extensive product portfolio in ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced that it is scheduled to speak ... York City. The presentation is scheduled for Tuesday, September ... The presentation will be webcast live during the conference ...
... Sept. 8, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... SPX-106, achieved statistically significant reductions in VLDL and ...
Cached Medicine Technology:SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 2SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice 3
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is ... several years. He has recently announced that GoDaddy ( ... in 2014. , GoDaddy is a popular supplier of ... great hosting solutions at affordable rates. It offers three ... hosting plans depend on the length of the contract. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... News) -- The prevalence of psoriasis -- a chronic, inflammatory ... and obese kids, researchers have found. The Kaiser ... , also found that teens with psoriasis (regardless of their ... risk for heart disease. "This study suggests a ...
... 20 (HealthDay News) -- For the average listener, the ... speaker,s sexual orientation, a new study finds. "I,m not ... vowel," study lead author Erik C. Tracy, a cognitive psychologist ... the American Institute of Physics. "Other researchers have done various ...
... , FRIDAY, May 20 (HealthDay News) -- All ... to 11 years old, according to new guidelines from the ... with a family history of premature cardiovascular disease or elevated ... as early as age 2. "It,s important that people ...
... Dr. Jeffrey M. Trent, F.A.C.M.G., a nationally recognized ... has been appointed Foreign Trade Counselor of Luxembourg in ... and Research Director of the Translational Genomics Research Institute ... Grand Rapids, Michigan. Both non-profit biomedical research institutes study ...
... News) -- Though a new study suggests that a dietary ... develop preeclampsia, the jury is still out over whether it ... it yet. Preeclampsia is a pregnancy complication ... hypertension. It affects about 5 percent of first pregnancies. ...
... SESSION I / Monday, May 23 / 8 ... Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations ... Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, ... SESSION II / Tuesday, May 24 / 8 ...
Cached Medicine News:Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2Health News:Straight or Gay? Vowels in Speech May Give it Away 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:TGen/VARI president Dr. Jeffrey Trent appointed Foreign Trade Counselor by Luxembourg 2Health News:Study Suggests Supplement May Protect Against Preeclampsia 2Health News:HealthCore presents ISPOR poster sessions 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: